IRVINE, Calif.--(BUSINESS WIRE)--Oct. 29, 2015--
Masimo
(NASDAQ: MASI) announced today that two new studies using Masimo
technologies were presented at the American Society of Anesthesiologists
(ASA) annual meeting in San Diego, California, October 24-28. The
conference is the largest gathering of anesthesiologists in the world.
Study Evaluating the EMMA Portable Capnometer in
Children Under General Anesthesia
Carbon dioxide levels in the blood reflect the degree of gas exchange
occurring in the lungs and provide a critical indictor of
cardio-respiratory function that aids in the assessment of the adequacy
of ventilation. In a study of 13 children (average age 18 months)
undergoing surgery, Dr. Yuko Nawa and colleagues from the Hokkaido
Medical Center for Child Health and Rehabilitation in Sapporo, Japan,
compared the end tidal carbon dioxide values (EtCO2) from the
Masimo EMMA portable capnometer and traditional sidestream capnography
(GE Patient Monitor).¹ Compared to sidestream capnography, the EMMA had
95% limits of agreement of -1.3 to 2.5 mm Hg, leading the investigators
to conclude that the EMMA has “good correlation with sidestream type
capnometer in children” and “may be useful for general anesthesia in
out-of-operating room or in case of cardiopulmonary resuscitation,
bedside respiratory care and patient transportation.”
Study Evaluating Pleth Variability Index in
Spontaneously Breathing Adults During Regional Anesthesia
Dexmedetomidine is an intravenous drug used to sedate patients during
surgery which can also cause hypertension or hypotension that may
increase patient risk. In a study of 42 spontaneously breathing patients
under regional anesthesia,2 Dr. Makoto Sato and colleagues
from Asahikawa Medical University in Hoikkado, Japan evaluated the
association of baseline pleth variability index (PVI) from Masimo SET®
pulse oximetry and dexmedetomidine-induced changes in blood pressure. A
baseline PVI≤15 had a 94% sensitivity, 85% specificity, and area under
the curve (AUC) of 0.93 (p=0.00002) for resulting hypertension. A
baseline PVI≥16 had an 83% sensitivity, 64% specificity, and area under
the curve (AUC) of 0.79 (p=0.0008) for resulting hypotension. The
investigators concluded, “PVI can predict dexmedetomidine-induced
changes in blood pressure in spontaneously breathing patients.”
For more information on the Masimo technology, go to www.masimo.com.
@MasimoInnovates
| #Masimo
1. Nawa Y, Chaki T, Tamashiro K, Sato M, Mizuno E, Yamakage M. Accuracy
of Portable Capnometer in Children. Proceedings of the American Society
of Anesthesiologists, Oct. 27, 2015, San Diego, A4049, Room Upper 10.
2. Sato M, Kunisawa T, Kurosawa A, Sasakawa T, Iwasaki H. Pulse
oximeter-derived pleth variability index can predict
dexmedetomidine-induced changes in blood pressure in spontaneously
breathing patients. Proceedings of the American Society of
Anesthesiologists, Oct. 26, 2015, San Diego, A3153, Hall B2, Area B.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
which has been shown in multiple studies to significantly reduce false
alarms and accurately monitor for true alarms. The benefits of Masimo
SET® have been proven in more than 100 independent and objective studies
and it is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition
to SpO2, pulse rate, and perfusion index (PI). For the U.S. market, PVI
is a measure of dynamic changes in the perfusion index (PI) that occur
during the respiratory cycle. The PVI calculation is accomplished by
measuring changes in PI over a time interval where one or more complete
respiratory cycles have occurred. PVI is displayed as a percent
(0-100%). PVI may show changes that reflect physiologic factors such as
vascular tone, circulating blood volume and intrathoracic pressure
excursions. The utility of PVI is unknown at this time and requires
further clinical studies. Technical factors that may affect PVI include
probe malposition and patient motion. The indications for EMMA include
the following: 1) The EMMA Emergency Capnometer Monitor measures,
displays and monitors carbon dioxide concentration and respiratory rate
during anesthesia, recovery and respiratory care. It may be used in the
operating suite, intensive care unit, patient room, clinic, emergency
medicine and emergency transport settings for adult, pediatric and
infant patients. 2) The EMMA Emergency Capnometer Analyzer measures and
displays carbon dioxide concentration and respiratory rate during
anesthesia, recovery and respiratory care. It may be used in the
operating suite, intensive care unit, patient room, clinic, emergency
medicine and emergency transport settings for adult, pediatric and
infant patients. Additional information about Masimo and its products
may be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb®) contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment without
causing invasive trauma in all patients and in every clinical situation;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151029005697/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com